Skip to main content
Hengrui Pharma logo

Hengrui Pharma — Investor Relations & Filings

Ticker · 600276 ISIN · CNE0000014W7 LEI · 2549003BT1XS3SE3E448 HKEX Manufacturing
Open in API
Filings indexed 2,705 across all filing types
Latest filing 2026-04-02 Regulatory Filings
Country CN China
Listing HKEX 600276

About Hengrui Pharma

https://www.hrs.com

Hengrui Pharma is an innovative, global pharmaceutical company focused on the research, development, manufacturing, and commercialization of medicines. The company specializes in therapies for oncology, surgical applications, and interventional imaging. With a strong commitment to R&D, Hengrui has developed and commercialized numerous new molecular entities and is expanding its portfolio to address unmet medical needs in international markets. Its core activities revolve around creating high-quality and accessible treatments, particularly in the field of cancer therapy.

Recent filings

Filing Released Lang Actions
Monthly Return of Equity Issuer on Movements in Securities for the month ended March 31, 2026
Regulatory Filings Classification · 94% confidence The document is a recurring monthly return (Form FF301) filed with the Hong Kong Stock Exchange detailing movements in authorised/registered share capital, issued shares, treasury shares, public float confirmations, and share repurchase activity. It is not an AGM presentation, earnings release, annual or interim report, nor a one‐off proxy/merger/dividend notice. It represents a mandatory regulatory filing under HKEX Listing Rules (Chapter 19B) and does not fit more specific categories (e.g., a single share issue announcement or director dealing notice). Therefore it falls under the general “Regulatory Filings” category.
2026-04-02 English
恒瑞医药关于召开2025年年度业绩暨现金分红说明会的公告
AGM Information Classification · 90% confidence The document is an announcement about a scheduled investor meeting to discuss the company's 2025 annual performance and cash dividend. It specifies the date, time, format (video recording and online interaction), and participation details for the meeting. The document does not contain the actual annual report or financial statements but rather informs investors about the upcoming event where such information will be discussed. The document length is short (1352 characters), and it serves as a notice for the meeting rather than the meeting materials or the report itself. Therefore, it fits the category of an Investor Presentation announcement or meeting notice. However, since it is primarily an announcement of the meeting and not the presentation itself, the best fitting category is AGM Information (AGM-R), which includes presentations and materials shared during the Annual General Meeting or similar investor meetings. Confidence is high due to clear meeting details and purpose.
2026-03-27 Chinese
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Report Publication Announcement Classification · 88% confidence The document is very short (under 300 characters) and simply states that an announcement has been published elsewhere without including any substantive report content. This fits the pattern of a Report Publication Announcement rather than the report itself.
2026-03-27 English
恒瑞医药关于获得药物临床试验批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Jiangsu Hengrui Medicine Co., Ltd. regarding the receipt of a drug clinical trial approval notice from the National Medical Products Administration. It details the drug's basic information, approval status, and risk warnings. The document is short (1015 characters) and serves as an official announcement of a regulatory approval event rather than a detailed financial or management report. It does not contain financial statements, management discussion, or detailed investor presentation content. It is not a report publication announcement since it contains substantive information about the approval. The content fits best under Regulatory Filings (RNS) as it is a regulatory announcement about clinical trial approval, which does not fit other specific categories like Annual Report, Earnings Release, or Management Reports.
2026-03-26 Chinese
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Report Publication Announcement Classification · 85% confidence The document is extremely short (242 characters) and merely states that an announcement has been published in another section of the website. It does not contain any substantive financial or corporate disclosure itself, but serves to notify readers of the publication of an issuer’s announcement. This matches the definition of a Report Publication Announcement (RPA).
2026-03-26 English
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Report Publication Announcement Classification · 95% confidence The document is extremely short (under 5,000 characters) and simply states that an announcement has been published on the issuer’s website without containing substantive report content. It is announcing the publication of a document rather than providing the report itself.
2026-03-25 English

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.